PCSA: Processa Pharma Consensus Target

This daily price chart for Processa Pharmaceuticals (PCSA), with a metric of 25.07, reflects the operations of a biopharmaceutical business developing personalized chemotherapy regimens using AI. The asset remains relatively insulated from market volatility, as its success depends on medical test results and product implementation. Processa Pharmaceuticals is accelerating FDA certification by modifying the compositions of established medications to enhance their safety.

processapharmaceuticals.com (PCSA): Analyst Consensus Forecast from 07/04/2022 to 11/10/2026

Metric breakdowns and analytics for Processa Pharmaceuticals (PCSA)

- share price and expert price forecast:

Quote Chart processapharmaceuticals.com|PCSA - Analyst Consensus Forecast

- market capitalization information:

Market Valuation Processa Pharma|PCSA - Total Company Value

- book value of equity indicators:

Net Assets per Share Processa Pharmaceuticals|PCSA - Book Capitalization|Market Capitalization to Book Value Ratio processapharmaceuticals.com|PCSA - Company Total Assets

- issuer credit burden and liquidity indicators:

Debt to Equity Processa Pharmaceuticals|PCSA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital processapharmaceuticals.com|PCSA - Company Aggregate Debts|Debts to Book Value Processa Pharma|PCSA - Company Long-Term Debts|Company Short-Term Debts Processa Pharmaceuticals|Interim Coverage Ratio processapharmaceuticals.com

- net income and valuation ratios data:

PCSA - Net Income|Future Net Profit Processa Pharmaceuticals|PCSA - Price to Earnings Ratio|Future Price to Earnings Multiple processapharmaceuticals.com|PCSA - PEG Multiple|Enterprise Value to EBITDA Ratio Processa Pharma|PCSA - Operating profit EBITDA|Net earnings per share (EPS TTM) Processa Pharmaceuticals|PCSA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months processapharmaceuticals.com|PCSA - Earnings growth in current year|Expected earnings per share growth for next year Processa Pharmaceuticals

General company analysis:PCSA - Processa Pharmaceuticals Inc.

Product sample of Processa Pharmaceuticals, Inc.

Investors verify issuer reliability through the dynamics of fundamental valuations, filtering out market noise. The current consensus valuation of the stock aggregates weighted average expert forecasts for fair value, reflecting the potential of Processa Pharmaceuticals (PCSA) to optimize anti-tumor drug formulas for accelerated FDA approval. The stable trend of this indicator confirms the resilience of the business model, while sharp deviations signal a revision of market expectations regarding the efficacy of new developments.

Competing companies